Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of Brucella abortus in BALB/c mice

Vaccine

Volumn 32, Issue 35, 2014, Pages 4537-4542

  Jain, Shikha ^a   Afley, Prachiti ^a   Dohre, Sudhir K ^a   Saxena, Nandita ^a   Kumar, Subodh ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Brucella abortus; DNA vaccine; In vivo electroporation; L9 protein; Prime boost vaccination

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; PLASMID DNA; RECOMBINANT PROTEIN; RIBOSOMAL PROTEIN L9; RIBOSOME PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; BRUCELLA VACCINE; CYTOKINE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BRUCELLA ABORTUS; BRUCELLOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DNA IMMUNIZATION; DRUG EFFICACY; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; SECRETION (PROCESS); SPLEEN;

ANIMALS; ANTIBODIES, BACTERIAL; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; ELECTROPORATION; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE, INBRED BALB C; RIBOSOMAL PROTEINS; SPLEEN; VACCINES, DNA;

EID: 84904395673     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.012     Document Type: Article

References (48)

1. Carvalho Neta A.V.M.J., Xavier M.N., Paixão T.A., Lage A.P., Santos R.L. Pathogenesis of bovine brucellosis. Vet J 2010, 184:146-155.
2. Araya L.N., Elzer P.H., Rowe G.E., Enright F.M., Winter A.J. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol 1989, 143:3330-3337.
3. Goenka R., Parent M.A., Elzer P.H., Baldwin C.L. B cell-deficient mice display markedly enhanced resistance to the intracellular bacterium Brucella abortus. J Infect Dis 2011, 203:1136-1146.
4. Schurig G.G., Roop R.M., Bagchi T., Boyle S., Buhrman D., Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol 1991, 28:171-188.
5. Stevens M.G., Hennager S.G., Olsen S.C., Cheville N.F. Serologic responses in diagnostic tests for brucellosis in cattle vaccinated with Brucella abortus 19 or RB51. J Clin Microbiol 1994, 32:1065-1066.
6. Berkelman R.L. Human illness associated with use of veterinary vaccines. Clin Infect Dis 2003, 37:407-414.
7. Perkins S.D., Smither S.J., Atkins H.S. Towards a Brucella vaccine for humans. FEMS Microbiol Rev 2010, 34:379-394.
8. Pappas G., Panagopoulou P., Christou L., Akritidis N. Brucella as a biological weapon. Cell Mol Life Sci 2006, 63:2229-2236.
9. Luxembourg A., Hannaman D., Nolan E., Ellefsen B., Nakamura G., Chau L., et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 2008, 26:5216-5222.
10. Flingai S., Czerwonko M., Goodman J., Kudchodkar S.B., Muthumani K., Weiner D.B. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013, 4:354.
11. He Y., Xiang Z. Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN. Immunome Res 2010, 6(Suppl. 1):S5.
12. Onate A.A., Cespedes S., Cabrera A., Rivers R., Gonzalez A., Munoz C., et al. A DNA vaccine encoding Cu, Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2003, 71:4857-4861.
13. Velikovsky C.A., Cassataro J., Giambartolomei G.H., Goldbaum F.A., Estein S., Bowden R.A., et al. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2002, 70:2507-2511.
14. Luo D., Ni B., Li P., Shi W., Zhang S., Han Y., et al. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infect Immun 2006, 74:2734-2741.
15. Cassataro J., Velikovsky C.A., Bruno L., Estein S.M., de la Barrera S., Bowden R., et al. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clin Vaccine Immunol 2007, 14:869-874.
16. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164:4635-4640.
17. Babiuk S., Baca-Estrada M.E., Foldvari M., Storms M., Rabussay D., Widera G., et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002, 20:3399-3408.
18. Scheerlinck J.P., Karlis J., Tjelle T.E., Presidente P.J., Mathiesen I., Newton S.E. In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 2004, 22:1820-1825.
19. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000, 21:163-165.
20. Ramsay A.J., Leong K.H., Ramshaw I.A. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol Cell Biol 1997, 75:382-388.
21. Feng C.G., Palendira U., Demangel C., Spratt J.M., Malin A.S., Britton W.J. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect Immun 2001, 69:4174-4176.
22. Barnett S.W., Rajasekar S., Legg H., Doe B., Fuller D.H., Haynes J.R., et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997, 15:869-873.
23. Tanghe A., D'Souza S., Rosseels V., Denis O., Ottenhoff T.H., Dalemans W., et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001, 69:3041-3047.
24. Dunachie S.J., Hill A.V. Prime-boost strategies for malaria vaccine development. J Exp Biol 2003, 206:3771-3779.
25. Jain S., Kumar S., Dohre S., Afley P., Sengupta N., Alam S.I. Identification of a protective protein from stationary-phase exoproteome of Brucella abortus. Pathog Dis 2014, 70:75-83.
26. Kumar S., Balakrishna K., Agarwal G.S., Merwyn S., Rai G.P., Batra H.V., et al. Th1-type immune response to infection by pYV-cured phoP-phoQ null mutant of Yersinia pseudotuberculosis is defective in mouse model. Antonie Van Leeuwenhoek 2009, 95:91-100.
27. Cassataro J., Estein S.M., Pasquevich K.A., Velikovsky C.A., de la Barrera S., Bowden R., et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun 2005, 73:8079-8088.
28. Oliveira S.C., Splitter G.A. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 1996, 14:959-962.
29. Delpino M.V., Estein S.M., Fossati C.A., Baldi P.C., Cassataro J. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 2007, 25:6721-6729.
30. Velikovsky C.A., Goldbaum F.A., Cassataro J., Estein S., Bowden R.A., Bruno L., et al. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect Immun 2003, 71:5750-5755.
31. Harms J.S., Durward M.A., Magnani D.M., Splitter G.A. Evaluation of recombinant invasive, non-pathogenic Escherichia coli as a vaccine vector against the intracellular pathogen, Brucella. J Immune Based Ther Vaccines 2009, 7:1.
32. Zhao Z., Li M., Luo D., Xing L., Wu S., Duan Y., et al. Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. Vaccine 2009, 27:5214-5219.
33. He Y., Vemulapalli R., Schurig G.G. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu, Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infect Immun 2002, 70:2535-2543.
34. Cabrera A., Saez D., Cespedes S., Andrews E., Onate A. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology 2009, 214:467-474.
35. Tabynov K., Sansyzbay A., Kydyrbayev Z., Yespembetov B., Ryskeldinova S., Zinina N., et al. Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J 2014, 11:69.
36. Riquelme-Neira R., Retamal-Diaz A., Acuna F., Riquelme P., Rivera A., Saez D., et al. Protective effect of a DNA vaccine containing an open reading frame with homology to an ABC-type transporter present in the genomic island 3 of Brucella abortus in BALB/c mice. Vaccine 2013, 31:3663-3667.
37. Eze M.O., Yuan L., Crawford R.M., Paranavitana C.M., Hadfield T.L., Bhattacharjee A.K., et al. Effects of opsonization and gamma interferon on growth of Brucella melitensis 16M in mouse peritoneal macrophages in vitro. Infect Immun 2000, 68:257-263.
38. Baldwin C.L., Goenka R. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection. Crit Rev Immunol 2006, 26:407-442.
39. Zhan Y., Kelso A., Cheers C. Cytokine production in the murine response to Brucella infection or immunization with antigenic extracts. Immunology 1993, 80:458-464.
40. Gu W., Wang X., Qiu H., Cui B., Zhao S., Zheng H., et al. Comparison of cytokine immune responses to Brucella abortus and Yersinia enterocolitica serotype O:9 infections in BALB/c mice. Infect Immun 2013, 81:4392-4398.
41. Murphy E.A., Parent M., Sathiyaseelan J., Jiang X., Baldwin C.L. Immune control of Brucella abortus 2308 infections in BALB/c mice. FEMS Immunol Med Microbiol 2001, 32:85-88.
42. Zhan Y., Liu Z., Cheers C. Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms. Infect Immun 1996, 64:2782-2786.
43. Paranavitana C., Zelazowska E., Izadjoo M., Hoover D. Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice. Cytokine 2005, 30:86-92.
44. Murphy E.A., Sathiyaseelan J., Parent M.A., Zou B., Baldwin C.L. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 2001, 103:511-518.
45. Oliveira S.C.H.J., Rech E.L., Rodarte R.S., Bocca A.L., Goes A.M., Splitter G.A. The role of T cell subsets and cytokines in the regulation of intracellular bacterial infection. Braz J Med Biol Res 1998, 31:77-84.
46. Yingst S.L., Izadjoo M., Hoover D.L. CD8 knockout mice are protected from challenge by vaccination with WR201, a live attenuated mutant of Brucella melitensis. Clin Dev Immunol 2013, 2013:686919.
47. Vitry M.A., De Trez C., Goriely S., Dumoutier L., Akira S., Ryffel B., et al. Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B, cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice. Infect Immun 2012, 80:4271-4280.
48. Estein S.M., Fiorentino M.A., Paolicchi F.A., Clausse M., Manazza J., Cassataro J., et al. The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams. Vaccine 2009, 27:6704-6711.